Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.62 |
| ▸ | HINT1 | P49773 | 4/20 | 0.59 |
| ▸ | NT5E | P21589 | 1/20 | 0.57 |
| ▸ | PNP | P00491 | 1/20 | 0.56 |
| ▸ | GSK3A | P49840 | 2/20 | 0.54 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.54 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.54 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.53 |
| ▸ | TGM2 | P21980 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.52 |
| ▸ | STING1 | Q86WV6 | 2/20 | 0.52 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.52 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19831524 | 1.00 | HPGD (0.62) | HPGDHINT1NT5EPNPGSK3A | |
| SCHEMBL1115914 | 1.00 | HPGD (0.62) | HPGDHINT1NT5EPNPGSK3A | |
| SCHEMBL14143259 | 1.00 | HPGD (0.62) | HPGDHINT1NT5EPNPGSK3A | |
| SCHEMBL14440994 | 0.96 | HPGD (0.63) | HPGDHINT1NT5EPNPGSK3A | |
| SCHEMBL1738417 | 0.93 | HPGD (0.64) | HPGDHINT1NT5EPNPGSK3A | |
| SCHEMBL1738416 | 0.93 | HPGD (0.64) | HPGDHINT1NT5EPNPGSK3A | |
| SCHEMBL1738418 | 0.93 | HPGD (0.64) | HPGDHINT1NT5EPNPGSK3A | |
| SCHEMBL26208536 | 0.93 | HPGD (0.64) | HPGDHINT1NT5EPNPGSK3A | |
| SCHEMBL16317882 | 0.93 | HPGD (0.64) | HPGDHINT1NT5EPNPGSK3A | |
| SCHEMBL12031280 | 0.93 | HPGD (0.64) | HPGDHINT1NT5EPNPGSK3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9884885-B2 | Synthesis of labile base protected-modified deoxy and modified ribo nucleosides, corresponding phosphoramidites and supports and their use in high purity oligonucleotide synthesis | CHEMGENES CORPORATION (US) | 2018-02-06 | — | — | US | disclosed |
| US-20120065386-A1 | SYNTHESIS OF LABILE BASE PROTECTED - MODIFIED DEOXY & MODIFIED RIBO NUCLEOSIDES, CORRESPONDING PHOSPHORAMIDITES AND SUPPORTS AND THEIR USE IN HIGH PURITY OLIGONUCLEOTIDE SYNTHESIS | CHEMGENES CORPORATION | 2012-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065386-A1 | SYNTHESIS OF LABILE BASE PROTECTED - MODIFIED DEOXY & MODIFIED RIBO NUCLEOSIDES, CORRESPONDING PHOSPHORAMIDITES AND SUPPORTS AND THEIR USE IN HIGH PURITY OLIGONUCLEOTIDE SYNTHESIS | RNMT, POLRMT, RNGTT | HPGD 1464/4885HINT1 494/4885NT5E 324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.